Compare YieldMax AMD Option Income Strategy ETF (AMDY) vs Amgen, Inc. (AMGN) Price & Performance

YieldMax AMD Option Income Strategy ETFTrade

Amgen, Inc.Trade

Price performance (Past 24H)

Key statistics

YieldMax AMD Option Income Strategy ETF vs Amgen, Inc. — how do they compare? YieldMax AMD Option Income Strategy ETF trades at $45.97, while Amgen, Inc. trades at $416.03 (market cap $224.14B). The key difference: Amgen, Inc. pays a 2.43% dividend while YieldMax AMD Option Income Strategy ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, YieldMax AMD Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.

	AMDY	AMGN
Sector	Income / Options Overlay	Health
52-Week High	$59.52	$417.20
52-Week Low	$29.80	$271.18
Market Cap	—	$224.14B
Enterprise Value	—	$267.45B
Dividend Yield	—	2.43%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

YieldMax AMD Option Income Strategy ETF

No Aura AI signal available yet.

Amgen, Inc.

Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.

Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

AMDY

YieldMax AMD Option Income ETF posts 127% return but rated HOLD amid better AMD stock upside potential.Seeking Alpha · 2 days agoNeutral View details →

AMGN

BioCryst hits profitability with strong Q2 revenue, sparking takeover interest in rare disease biotech.24/7 Wall Street · 1 day agoBullish View details →

About YieldMax AMD Option Income Strategy ETF

AMDY is an active ETF that seeks to generate weekly income by selling call options on AMD stock. It aims to provide investors with high yield while maintaining exposure to the price movements of Advanced Micro Devices.

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).